Adrian Adams
Independent ChairpersonMr. Adrian Adams served as the Chairman of Board of Directors at Impel Pharmaceuticals Inc. (formerly known as Impel NeuroPharma, Inc.) since January 08, 2020 until November 4, 2023 and also served as its President and Chief Executive Officer since May 05, 2020 until November 4, 2023. Mr. Adams serves as an Independent Chairperson of Akebia Therapeutics, Inc. since December 12, 2018.He served as Chief Executive Officer at Tribute Pharmaceuticals Canada, Inc. in February 2016 to January 2019 and served as a member of the board of directors from February 2016 to April 2019. He served as the Chief Executive Officer of Old API Wind-down Ltd. (formerly, Aralez Pharmaceuticals Inc.) since February 5, 2016 until January 31, 2019 and served as its Director since December 11, 2015 until May 30, 2019. He served as Chief Executive Officer and a Director of Pozen Inc. from May 2015 to February 5, 2016 and served as its Consultant from April 2, 2015 to May 31, 2015. Mr. Adams' position as Chief Executive Officer of Pozen, along with his service in the pharmaceutical industry in Chief Executive positions, enables him to provide important insights regarding the operations of Pozen and the pharmaceutical industry generally, including finance, marketing, strategic planning and senior management personnel matters. He served as the Chief Executive Officer and President at Auxilium Pharmaceuticals Inc. from December 8, 2011 to January 29, 2015. He served as the Chief Executive Officer and Director of Neurologix Inc. from September 19, 2011 to November 30, 2011. He served as the Chief Executive Officer and President of Inspire Pharmaceuticals, Inc. from February 22, 2010 to May 2011. He served as an Executive Officer of Dainippon Sumitomo Pharma Co., Ltd. until February 2010. Mr. Adams served as the Chief Executive Officer of Sunovion Pharmaceuticals Inc. from May 15, 2007 to February 19, 2010 and served as its President from March 1, 2007 to February 19, 2010. He served as Chief Operating Officer at Sunovion Pharmaceuticals Inc. since March 2007 until May 2007 and served as its Executive Director since March 2007 until February 19, 2010. Mr. Adams served as the Chief Operating Officer of Sepracor, Inc. from March 2007 to May 2007. Previously, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from March 2007 and May 2007, respectively, until February 2010, when Sepracor was acquired by Dainippon Sumitomo Pharma Co., Ltd. Mr. Adams served as the Chief Executive Officer of KOS Pharmaceuticals Inc., from January 1, 2002 to December 2006 and served as its President and Chief Operating Officer from April 26, 2001 to December 2006. Mr. Adams served as the President and Chief Executive Officer of Novartis Pharmaceuticals UK from 1999 to 2001. Mr. Adams served at SmithKline Beecham Pharmaceuticals from 1992 to 1999 in various capacities, including President and Chief Executive Officer of Canadian subsidiaries. His assignments at SmithKline Beecham included Vice President and Director of Worldwide Marketing in the US and Director and Vice President of Sales and Marketing in the United Kingdom. He is a highly qualified pharmaceutical executive who has successfully led the growth and corporate development of two publicly traded companies. He has strong skills in commercialization, business development and global Partnerships, including experience in licensing and developing respiratory products and an excellent understanding of the evolving specialty pharmaceutical market. Mr. Adams began his career at ICI Pharmaceuticals, where he rose from Research Laboratory Assistant to Director of Sales and Marketing. During his career he has worked in most therapeutic areas and has been instrumental in a number of major global and national product launches including Paxil, Famvir, Coreg, Diovan, Tenormin and Zestril. Mr. Adams has vast experience in pharmaceutical executive leadership with a record of successfully building organizations, delivering successful results against short, medium and long-term goals and creating shareholder value. Having spent his entire career in the pharmaceutical industry, Mr. Adams has a broad background encompassing research, sales, marketing, international and national product management, business development, general management and he has extensive senior management experience. He has been the Chairman of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since February 2013. He served as the Chairman of Neurologix Inc. from September 19, 2011 to November 30, 2011. He served as the Chairman of Arisaph Pharmaceuticals, Inc. since 2005 and served as its Director. Mr. Adams serves as a Director of PhRMA. He has been a Director of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since February 11, 2013. He served as a Director of Amylin Pharmaceuticals, LLC from October 2007 to August 2012. He served as a Director of Auxilium Pharmaceuticals Inc. from December 7, 2011 to January 29, 2015. He served as a Director at Inspire Pharmaceuticals, Inc. from February 22, 2010 until May 2011. He served as an Executive Director of Sepracor, Inc. from March 2007 to February 19, 2010. He served as a Director of KOS Pharmaceuticals Inc. from January 01, 2002 to December 2006. He served as Director at Neurocrine Biosciences Inc. from December 5, 2005 to February 20, 2007. He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree. Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the U. K.
Positions
- Company NameAkebia Therapeutics, Inc.Stock CodeAKBAPositionIndependent ChairpersonColleagues
- JPJohn P. ButlerCEO, President & Director
- AAAdrian AdamsIndependent Chairperson
- EJErik John OstrowskiChief Business Officer, Senior VP, CFO & Treasurer
- SKSteven Keith BurkeSenior VP and Chief Research & Development Officer
- RCRichard C. MalabreSenior VP & Chief Accounting Officer
- JMJustin McCueSenior VP & Chief Technology Officer
- CSCynthia SmithIndependent Director
- MWMichael W. RogersIndependent Director
- RERonald E. FriesonIndependent Director
- Company NameTalphera, Inc.Stock CodeTLPHPositionIndependent Chairman
